RESEARKA

HOME AGENT PAPERS ALPHA DECISIONS RUBRIC METHODS SUBMIT ABOUT

CLAIM CARDS

Claim Cards

Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.

Filtered to publication bd4ddec9-e10e-445f-bf0b-a5399dfae223

This synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Contradiction: none

Sources: 5

This structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape.

Contradiction: none

Sources: 5

Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse.

Contradiction: none

Sources: 5

The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation.

Contradiction: none

Sources: 5

Evidence-abstraction note.** The 41 retained reference papers are not 41 independent primary clinical trials: 41 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

Contradiction: none

Sources: 5

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-immune_age-v06-DAILY-2026-06-02T08-03-13Z`.

Contradiction: none

Sources: 5

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Contradiction: none

Sources: 5

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.

Contradiction: none

Sources: 5

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune, immune and inflammation, longevity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

Contradiction: none

Sources: 5

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

Contradiction: none

Sources: 5

Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Contradiction: none

Sources: 5

| Contextual Adjacent Evidence | n=1; claims=2 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

Contradiction: none

Sources: 5

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contradiction: none

Sources: 5

27 included sources were assigned to this outcome class. Directional coding: null=27. Directness coding: indirect=25, mechanistic=2.

Contradiction: none

Sources: 5

8 included sources were assigned to this outcome class. Directional coding: null=8. Directness coding: indirect=7, mechanistic=1.

Contradiction: none

Sources: 5

3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3.

Contradiction: none

Sources: 5

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Contradiction: none

Sources: 5

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Contradiction: none

Sources: 5

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Contradiction: none

Sources: 5

Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Contradiction: none

Sources: 5

A primary limitation is the absence of large, prospective, randomized controlled trials designed to test immune aging interventions against hard clinical endpoints. The curated corpus is overwhelmingly composed of observational cohort studies and exploratory biomarker analyses, such as Nakanjako 2024 and Davies 2025, which report associations between immune markers and age or disease state. There are no trials in this corpus that randomize an intervention to slow immune aging and follow participants for outcomes like all-cause mortality, incident frailty, or infection rates over several years. Consequently, the synthesis can describe correlations and mechanistic plausibility but cannot provide causal evidence that modifying these immune parameters translates into improved long-term health or longevity. This absence represents a critical gap, as the clinical relevance of any immune age biomarker remains uncertain without evidence from an intervention trial demonstrating a causal benefit.

Contradiction: none

Sources: 5

The evidence base is also limited by its heavy reliance on findings from single studies for specific outcomes, which precludes internal replication within the corpus. For instance, the association between social relationships and immune aging in early midlife is reported by only one source, Rob 2025. Similarly, the connection between immune age and decreased antibody response to vaccination is based solely on Davies 2025. While these studies report statistically significant associations, the reliance on single studies for these particular claims means their robustness and generalizability cannot be corroborated by other independent analyses in this synthesis. This single-trial risk introduces uncertainty, as findings from one study may be influenced by unique cohort characteristics, analytical choices, or chance, and require validation in distinct populations.

Contradiction: none

Sources: 5

Finally, the corpus primarily characterizes immune aging through cellular and molecular profiling endpoints, with a notable scarcity of evidence linking these markers to clinically relevant functional outcomes. Studies such as Fang 2025 and Brode 2023 provide detailed assessments of TCR repertoire diversity and immune cell subsets, which are mechanistic indicators. However, there is limited direct evidence within the corpus connecting these specific biomarker profiles to tangible patient-centered outcomes like physical function, disability, or infection susceptibility. While Noppert 2023 links a marker of immune aging (CD8+:CD4+ ratio) to disability prevalence, this represents a bridge between a surrogate marker and a clinical outcome, a link that is not consistently established across the evidence base for all proposed biomarkers of immune age. The synthesis is therefore largely built upon a foundation of surrogate endpoints (Ioannidis 2005).

Contradiction: none

Sources: 5

For immune age, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support immune age as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

Contradiction: none

Sources: 5

This synthesis maps 41 included sources on Immune age across 6 outcome classes and 382 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Contradiction: none

Sources: 5

Across 41 curated reference papers, the evidence base for Immune age shows a context-dependent profile. Null findings dominate: immune inflammation, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Immune age anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

Contradiction: none

Sources: 5

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Contradiction: none

Sources: 5

| contextual adjacent evidence | 0 | 1 | null | direct interventional hard-endpoint gap |

Contradiction: none

Sources: 5

| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |

Contradiction: none

Sources: 5

| immune and inflammation | 0 | 27 | null | direct interventional hard-endpoint gap |

Contradiction: none

Sources: 5